The spectrum of sclerosing cholangitis and the relevance of IgG4 elevations in routine practice

American Journal of Gastroenterology

Volumn 107, Issue 1, 2012, Pages 56-63

  Alswat, Khalid ^a,b   Al Harthy, Nadya ^a   Mazrani, Waseem ^c   Alshumrani, Ghazi ^c   Jhaveri, Kartik ^c   Hirschfield, Gideon M ^a,c  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; IMMUNOGLOBULIN G4;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE PANCREATITIS; CHOLELITHIASIS; CLINICAL PRACTICE; ENTERITIS; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATITIS; PORTAL VEIN THROMBOSIS; PORTOENTEROSTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCLEROSING CHOLANGITIS; SEX DIFFERENCE;

ADULT; CHOLANGITIS, SCLEROSING; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES;

EID: 84855437031     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.375     Document Type: Article

References (26)

1. Abdalian R, Heathcote EJ. Sclerosing cholangitis: a focus on secondary causes. Hepatology 2006; 44: 1063-74. (Pubitemid 44748357)
2. Chapman R, Fevery J, Kalloo A et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-78.
3. European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-67.
4. Hirschfield GM, Heathcote EJ, Gershwin ME. Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology 2010; 139: 1481-96.
5. Weismuller TJ, Wedemeyer J, Kubicka S et al. The challenges in primary sclerosing cholangitis-aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol 2008; 48 Suppl 1: S38-57.
6. Karlsen TH, Schrumpf E, Boberg KM. Primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2010; 24: 655-66.
7. Karlsen TH, Schrumpf E, Boberg KM. Update on primary sclerosing cholangitis. Dig Liver Dis 2010; 42: 390-400.
8. Talwalkar JA, Lindor KD. Natural history and prognostic models in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2001; 15: 563-75. (Pubitemid 32747011)
9. Tischendorf JJ, Hecker H, Kruger M et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol 2007; 102: 107-14. (Pubitemid 46072050)
10. Ponsioen CY, Vrouenraets SM, Prawirodirdjo W et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 2002; 51: 562-6.
11. Petrovic BD, Nikolaidis P, Hammond NA et al. Correlation between findings on MRCP and gadolinium-enhanced MR of the liver and a survival model for primary sclerosing cholangitis. Dig Dis Sci 2007; 52: 3499-506. (Pubitemid 350077180)
12. Ponsioen CY, Reitsma JB, Boberg KM et al. Validation of a cholangiographic prognostic model in primary sclerosing cholangitis. Endoscopy 2010; 42: 742-7.
13. Lindor KD, Kowdley KV, Luketic VA et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50: 808-14.
14. Chapman RW. High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater? Hepato logy 2009; 50: 671-3.
15. Park DH, Kim MH, Chari ST. Recent advances in autoimmune pancreatitis. Gut 2009; 58: 1680-9.
16. Webster GJ, Pereira SP, Chapman RW. Autoimmune pancreatitis/IgG4- associated cholangitis and primary sclerosing cholangitis-overlapping or separate diseases? J Hepatol 2009; 51: 398-402.
17. Mendes FD, Jorgensen R, Keach J et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006; 101: 2070-5. (Pubitemid 44337633)
18. Takikawa H, Takamori Y, Tanaka A et al. Analysis of 388 cases of primary sclerosing cholangitis in Japan; presence of a subgroup without pancreatic involvement in older patients. Hepatol Res 2004; 29: 153-9. (Pubitemid 38780131)
19. Manns MP, Czaja AJ, Gorham JD et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-213.
20. Hamano H, Kawa S, Horiuchi A et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001; 344: 732-8. (Pubitemid 32204991)
21. Pannala R, Chari ST. Corticosteroid treatment for autoimmune pancreatitis. Gut 2009; 58: 1438-9.
22. Bjornsson E, Chari S, Silveira M et al. Primary sclerosing cholangitis associated wiThelevated ImmunoglobulinG4: clinical characteristics and response to therapy. Am J Ther 2010; 18: 198-205.
23. Zhang L, Lewis JT, Abraham SC et al. IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis. Am J Surg Pathol 2010; 34: 88-94.
24. Aalberse RC, Stapel SO, Schuurman J et al. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009; 39: 469-77.
25. Ghazale A, Chari ST, Smyrk TC et al. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J Gastroenterol 2007; 102: 1646-53. (Pubitemid 47206688)
26. Oseini AM, Chaiteerakij R, Shire AM et al. The utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma. Hepatology 2011; doi:10.1002/hep.24487.